周一盘中，脑再生科技（RGC）股价大跌21.07%，延续了盘前的跌势。这一暴跌发生在该股此前两个交易日累计上涨近400%之后，引发了市场的广泛关注。
据悉，脑再生科技主要业务是开发三种液态标准化中药配方，用于治疗轻度、中度和重度的注意缺陷多动障碍（ADHD）和自闭症谱系障碍（ASD）患者。在近期的交易中，该股受到资本追捧，股价飙升至83.6美元的历史新高。然而，这种快速上涨后迅速出现大幅回调。
分析人士指出，脑再生科技股价的剧烈波动反映了投资者情绪的快速变化。在经历了近期的暴涨之后，部分投资者可能选择获利了结，导致股价承压。此外，考虑到公司的业务性质和市场环境，一些投资者可能对其估值产生疑虑，进而引发抛售。目前，市场将密切关注该公司的基本面发展和后续公告，以评估其长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.